Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 12OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 14Prostatic Neoplasms 10Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3HIV Infections 2Acquired Immunodeficiency Syndrome 2Sarcoma, Kaposi 1Recurrence 1Pain 1Myeloid Malignancies 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Leukemia, Lymphoid 1Dendritic Cell Sarcoma, Interdigitating 1Androgen-independent Prostate Cancer 1

Interventions

Dexamethasone 64Cyclophosphamide 35pomalidomide 34Lenalidomide 34Rituximab 31Bortezomib 30venetoclax 28fludarabine 27Gemcitabine 21carfilzomib 20Paclitaxel 19pembrolizumab 17daratumumab 17Cisplatin 16Carboplatin 15Calcium Dobesilate 14Azacitidine 14ibrutinib 12Docetaxel 12Cytarabine 12obinutuzumab 11Nivolumab 11durvalumab 10Injections 10Doxorubicin 10Bevacizumab 10selinexor 9cemiplimab 9blinatumomab 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × Mitoxantrone × Clear all
NCT00656084 2016-11-03

Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell

US Oncology Research

Phase 2 Completed
16 enrolled 9 charts
Lymphoid

Recurrence, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡